Intestinal and Hepatobiliary Transport of Ximelagatran and Its Metabolites in Pigs

The direct thrombin inhibitor melagatran is formed from ximelagatran via two intermediate metabolites, OH-melagatran and ethylmelagatran. The biotransformation of ximelagatran does not involve cytochrome P450 isoenzymes, and it has been suggested that a reported interaction with erythromycin may instead be mediated by transport proteins. A pig model that simultaneously enables bile collection, sampling from three blood vessels and perfusion of a jejunal segment, was used to investigate the biotransformation of ximelagatran and the effect of erythromycin on the intestinal and hepatobiliary transport of ximelagatran and its metabolites. The pigs received enteral ximelagatran (n = 6), enteral ximelagatran together with erythromycin (n = 6), i.v. ximelagatran (n = 4), or i.v. melagatran (n = 4). The plasma exposure of the intermediates was found to depend on the route of ximelagatran administration. Erythromycin increased the area under the plasma concentration-time curve (AUC) of melagatran by 45% and reduced its biliary clearance from 3.0 ± 1.3 to 1.5 ± 1.1 ml/min/kg. Extensive biliary exposure of melagatran and ethylmelagatran, mediated by active transport, was evident from the 100- and 1000-fold greater AUC, respectively, in bile than in plasma. Intestinal efflux transporters seemed to be of minor importance for the disposition of ximelagatran and its metabolites considering the high estimated fabs of ximelagatran (80 ± 20%) and the negligible amount of the compounds excreted in the perfused intestinal segment. These findings suggest that transporters located at the sinusoidal and/or canalicular membranes of hepatocytes determine the hepatic disposition of ximelagatran and its metabolites, and are likely to mediate the ximelagatran-erythromycin pharmacokinetic interaction.

[1]  H. Lennernäs,et al.  Improved understanding of the effect of food on drug absorption and bioavailability for lipophilic compounds using an intestinal pig perfusion model. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  Per Artursson,et al.  Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines , 2007, Drug Metabolism and Disposition.

[3]  M. Ahnoff,et al.  Determination of ximelagatran, melagatran and two intermediary metabolites in plasma by mixed-mode solid phase extraction and LC-MS/MS. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[4]  Martin F. Fromm,et al.  The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3 , 2007, Drug Metabolism and Disposition.

[5]  H. Lennernäs,et al.  The effect of pancreatic and biliary depletion on the in vivo pharmacokinetics of digoxin in pigs. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  Teruko Imai,et al.  Substrate Specificity of Carboxylesterase Isozymes and Their Contribution to Hydrolase Activity in Human Liver and Small Intestine , 2006, Drug Metabolism and Disposition.

[7]  L. Benet,et al.  IN VITRO AND IN VIVO CORRELATION OF HEPATIC TRANSPORTER EFFECTS ON ERYTHROMYCIN METABOLISM: CHARACTERIZING THE IMPORTANCE OF TRANSPORTER-ENZYME INTERPLAY , 2006, Drug Metabolism and Disposition.

[8]  H. Lennernäs,et al.  FIRST-PASS EFFECTS OF VERAPAMIL ON THE INTESTINAL ABSORPTION AND LIVER DISPOSITION OF FEXOFENADINE IN THE PORCINE MODEL , 2006, Drug Metabolism and Disposition.

[9]  J. Karlsson,et al.  INFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETION , 2006, Drug Metabolism and Disposition.

[10]  H. Gutmann,et al.  Primary porcine proximal tubular cells as a model for transepithelial drug transport in human kidney. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  T. Imai,et al.  IDENTIFICATION OF ESTERASES EXPRESSED IN CACO-2 CELLS AND EFFECTS OF THEIR HYDROLYZING ACTIVITY IN PREDICTING HUMAN INTESTINAL ABSORPTION , 2005, Drug Metabolism and Disposition.

[12]  Toshinori Yamamoto,et al.  POSSIBLE INVOLVEMENT OF ORGANIC ANION TRANSPORTER 2 ON THE INTERACTION OF THEOPHYLLINE WITH ERYTHROMYCIN IN THE HUMAN LIVER , 2005, Drug Metabolism and Disposition.

[13]  Y. Hofmann,et al.  CHARACTERIZATION AND PARTIAL PURIFICATION OF THE RAT AND HUMAN ENZYME SYSTEMS ACTIVE IN THE REDUCTION OF N-HYDROXYMELAGATRAN AND BENZAMIDOXIME , 2005, Drug Metabolism and Disposition.

[14]  D. Greenblatt,et al.  Interaction of Warfarin With Drugs, Natural Substances, and Foods , 2005, Journal of clinical pharmacology.

[15]  I. Sakuma,et al.  Combined compression and elongation experiments and non-linear modelling of liver tissue for surgical simulation , 2004, Medical and Biological Engineering and Computing.

[16]  D. Hawkins.  Limitations of Traditional Anticoagulants , 2004, Pharmacotherapy.

[17]  U. Bornscheuer,et al.  Recombinant porcine intestinal carboxylesterase: cloning from the pig liver esterase gene by site-directed mutagenesis, functional expression and characterization. , 2003, Protein engineering.

[18]  J. Drewe,et al.  Modulation of transendothelial permeability and expression of ATP-binding cassette transporters in cultured brain capillary endothelial cells by astrocytic factors and cell-culture conditions , 2003, Experimental Brain Research.

[19]  B. Clement,et al.  Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[20]  U. Bredberg,et al.  Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[21]  M. Ahnoff,et al.  Determination of ximelagatran, an oral direct thrombin inhibitor, its active metabolite melagatran, and the intermediate metabolites, in biological samples by liquid chromatography-mass spectrometry. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[22]  T. Friedberg,et al.  Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. , 2002, Biochemical pharmacology.

[23]  A. Nordgren,et al.  Glutamine concentration and tissue exchange with intravenously administered alpha-ketoglutaric acid and ammonium: a dose-response study in the pig. , 2002, Nutrition.

[24]  Tanja Eisenblätter,et al.  A new multidrug resistance protein at the blood-brain barrier. , 2002, Biochemical and biophysical research communications.

[25]  P. Taylor,et al.  Current progress on esterases: from molecular structure to function. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[26]  P. Anzenbacher,et al.  Cytochromes P450 and experimental models of drug metabolism , 2002, Journal of cellular and molecular medicine.

[27]  J. Polli,et al.  Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.

[28]  K. Vukovinsky,et al.  Comparison of the gravimetric, phenol red, and 14C-PEG-3350 methods to determine water absorption in the rat single-pass intestinal perfusion model , 2001, AAPS PharmSci.

[29]  A Abrahamsson,et al.  The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. , 2001, Thrombosis research.

[30]  C. Tei,et al.  Interactions of Ofloxacin and Erythromycin with the Multidrug Resistance Protein (MRP) in MRP-Overexpressing Human Leukemia Cells , 2000, Antimicrobial Agents and Chemotherapy.

[31]  R. Yumoto,et al.  Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. , 1998, European journal of pharmacology.

[32]  T. Kararli.  Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals , 1995, Biopharmaceutics & drug disposition.

[33]  H. Lennernäs,et al.  Regional Jejunal Perfusion, a New in Vivo Approach to Study Oral Drug Absorption in Man , 1995, Pharmaceutical Research.

[34]  T. R. Krishnan,et al.  Use of the domestic pig as a model for oral bioavailability and pharmacokinetic studies. , 1994, Biopharmaceutics & drug disposition.

[35]  L. Knutson,et al.  A new technique for segmental jejunal perfusion in man. , 1989, The American journal of gastroenterology.

[36]  Huadong Tang,et al.  Protein expression pattern of P–glycoprotein along the gastrointestinal tract of the yucatan micropig , 2004, Journal of biochemical and molecular toxicology.

[37]  L. Johansson,et al.  Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor , 2003, Clinical pharmacokinetics.

[38]  T. Andersson,et al.  Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions , 2003, Clinical pharmacokinetics.

[39]  M. Ekelund,et al.  Mucosal in vitro permeability in the intestinal tract of the pig, the rat, and man: species- and region-related differences. , 2000, Scandinavian journal of gastroenterology.

[40]  J Kvĕtina,et al.  Presence and activity of cytochrome P450 isoforms in minipig liver microsomes. Comparison with human liver samples. , 1998, Drug metabolism and disposition: the biological fate of chemicals.